At their different laboratories, they have studied the hormones that intervene in the process and regulate digestive metabolism, such as somatostatin, which inhibits the production of glucagon and insulin, and variants of glucagon, called GLP-1 and GLP-2, and verified that this homeostasis system could be an effective therapeutic target against type-2 diabetes
The difference comes down to scope
When the stomach and intestines move slowly, the contents of the digestive tract stay in the system longer
The injection protects your heart while supporting healthy weight loss
And, further, for patients with type 2 diabetes (T2DM) taking a GLP-1, the risks are reduced by about 60% and 50%, respectively
Trina Wilcox: Emily Moshinsky says, "My C-reactive protein levels have gotten to almost zero after microdosing